慢性骨髓性白血病的新治療 | 合法藥品大搜索

2018年12月31日—慢性骨髓性白血病(chronicmyeloidleukemia，CML)是骨髓造血細胞增生性...西元2001年，標靶藥物Glivec(imatinib)在CML治療上獲得卓越的成果， ...

You-An Shih, Wen-Hsun Lee, Hui-Chuan Hsiao, Hsiu-Mei Chang, Wei-Hsuan Huang Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease. Tyrosine kinase inhibitors (TKIs) are the initial targeted therapies for CML. Imatinib is the first generation of TKI which has been proven to be effective in BCR-ABL tyrosine kinase. As a result of mutations in the kinase domain of BCR-ABL, the second and the third generation of TKIs have been developed, such as nilotinib, dasatinib, bosutinib, ponatinib. They are approved for the treatment of newly diagnosed or imatinib-resistant or -intolerant CML. There are different selectivities for BCR-ABL, and different side effects for TKIs’. Appropriate medications could be chosen based on the need of patients’ spec...